36 stories from 10 sources

GLP-1 momentum grows as public health faces fresh tests

Day’s Recap

Supporting Articles

4:45 PMMarketWatch

Lilly’s revenue soars 48%, driven by demand for its GLP-1s

Summary

Eli Lilly’s revenue rose 48%, powered by stronger-than-expected demand for Mounjaro and Zepbound, its diabetes and weight-loss GLP-1 treatments.

The growth confirms that Lilly’s commercial momentum is concentrated in a fast-expanding but competitive drug

Why it matters

GLP-1 demand is reshaping Lilly’s growth profile and accelerating the broader shift toward obesity medicines as a major pharmaceutical market.

Link to Story

10:35 AMCNBC

Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge

Summary

Eli Lilly beat quarterly estimates as sales of its obesity drug Zepbound and diabetes treatment Mounjaro surged. It raised its 2026 revenue forecast to $85 billion to $87 billion, from $82 billion to $85 billion.

Lilly’s higher outlook shows that demand for its tirzepatide drugs is growing faster than previously

Why it matters

Lilly’s forecast points to GLP-1 drugs becoming an even larger driver of pharmaceutical sales and healthcare spending.

Link to Story

2 stories · 2 sources

3:28 PMCNBC

We're increasing our Eli Lilly price target after another beat-and-raise quarter

Summary

Analysts raised their Eli Lilly price target after the company exceeded expectations and increased its outlook again. Strong demand for its GLP-1 medicines remains the main driver of the bullish view.

Another beat-and-raise quarter strengthens the case that Lilly’s growth is becoming structural rather than a

Why it matters

Lilly’s performance shows how GLP-1 drugs are reshaping pharmaceutical earnings and investor expectations.

Link to Story

9:13 AMCNBC

Mexican jalapenos tied to Salmonella outbreak in 27 U.S. states

Summary

CDC and FDA are investigating a Salmonella outbreak linked to jalapenos from Mexico that has sickened 345 people across 27 states. A recall is underway.

The outbreak's multistate spread has triggered a coordinated federal investigation and product recall. Consumers, retailers,

Why it matters

The scale of the outbreak raises the risk of further illnesses before contaminated products are fully identified and removed.

Link to Story

6:46 PMAl Jazeera

Erica Schwartz confirmed as new CDC chief amid US agency turmoil

Summary

The Senate confirmed Erica Schwartz to lead the CDC as the agency faces political pressure and ongoing public health crises. Her appointment comes during a period of broader turmoil for the US public health agency.

Schwartz takes control of the CDC at a moment when political scrutiny could complicate its

Why it matters

The CDC's leadership change could affect the credibility and effectiveness of US public health responses.

Link to Story

5:31 PMFortune

Third time’s a charm for CDC director as Senate finally confirms Erica Schwartz as new agency head

Summary

The Senate confirmed Erica Schwartz as CDC director, making her the third Trump nominee for the position in 18 months.

The confirmation ends an 18-month succession of failed or short-lived efforts to fill the agency's

Why it matters

A confirmed director gives the CDC a clearer chain of command after prolonged uncertainty.

Link to Story

4:19 PMCNBC

Senate confirms Erica Schwartz as CDC director

Summary

The Senate confirmed Dr. Erica Schwartz as director of the Centers for Disease Control and Prevention, giving the Trump administration a rare success after repeated failures to fill senior health positions.

The confirmation puts the CDC under permanent leadership after a difficult period of staffing the

Why it matters

The CDC now has a confirmed director, but the appointment does not resolve the administration's wider struggle to staff key health posts.

Link to Story

3:08 PMStat News

Erica Schwartz confirmed as CDC director, filling nearly yearlong vacancy

Summary

Erica Schwartz was confirmed as CDC director after nearly a year without a permanent leader. She is the third nominee for the position since President Trump began his second term.

The confirmation ends a prolonged leadership gap but also underscores the instability surrounding the agency’s

Why it matters

A stable CDC leadership structure is essential for outbreak response, public communication, and trust in federal health guidance.

Link to Story

4 stories · 4 sources

10:18 PMStat News

FDA approves Moderna’s mRNA flu vaccine, the first to use the technology

Summary

The FDA has approved Moderna's influenza vaccine, making it the first licensed flu shot based on messenger RNA technology.

FDA approval moves mRNA flu vaccination from development into clinical use and gives Moderna a

Why it matters

The approval expands the mRNA platform beyond COVID-19 and could reshape how future seasonal flu vaccines are developed.

Link to Story

12:52 PMMarketWatch

How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?

Summary

Novo Nordisk created the leading GLP-1 weight-loss drug franchise, but Eli Lilly moved faster and captured control of the market. The reversal shows how quickly an apparent European pharmaceutical advantage can erode in a strategically important global industry.

Eli Lilly's success shifted pricing power, investor attention, and market momentum away from Novo Nordisk.

Why it matters

The GLP-1 race is becoming a test of Europe's ability to turn scientific breakthroughs into durable industrial power.

Link to Story

7:02 AMCNBC

Novo Nordisk CEO defends economics of Wegovy pill as lower prices weigh on sales; shares fall 5%

Summary

Novo Nordisk's CEO defended the commercial outlook for a daily Wegovy pill as falling prices and intensifying competition from Eli Lilly pressured sales and drove the company's shares lower. Investors remain unconvinced that the obesity-drug maker has a clear route back to durable growth.

Lower pricing is weakening the economics of Novo's core obesity franchise just as Lilly expands

Why it matters

The obesity-drug race is shifting from a supply-constrained growth story to a pricing and profitability contest.

Link to Story

5:15 AMBloomberg Markets

Wegovy Profitability Will Keep Improving, Novo CEO Says

Summary

Novo Nordisk says Wegovy is already generating decent profits and that margins should improve as the drug launches in more markets.

Improving profitability gives Novo room to expand Wegovy internationally despite the costs of manufacturing, distribution,

Why it matters

Wegovy’s economics support continued global expansion of obesity treatment, while increasing pressure on rivals and health budgets.

Link to Story

2 stories · 2 sources

5:57 AMBloomberg Markets

Ebola Outbreak: Why the Death Rate Is Rising as Patients Reach Care Too Late

Summary

The Ebola outbreak is appearing increasingly deadly because many patients are reaching treatment only after the disease has become critical.

Late presentation, rather than clear evidence of a more lethal virus, is driving the rise

Why it matters

A higher death rate may reflect failures in access and timing that can still be addressed through faster diagnosis and treatment.

Link to Story

1:46 PMStat News

STAT+: Once again, child dies in gene-editing trial in China, rekindling debate on transparency and safety

Summary

The delayed disclosure of another child's death in a gene-editing trial in China has renewed criticism of the country's clinical-trial transparency and safety practices. Experts are questioning whether a looser trial environment is allowing serious risks to remain hidden or underexamined.

The second reported death increases pressure for timely disclosure, independent oversight, and clearer evidence that

Why it matters

Pediatric gene-editing research cannot earn legitimacy if deaths emerge late and oversight remains difficult to assess.

Link to Story

4:05 PMStat News

STAT+: Federal regulators invite industry, researchers, and lobbyists to closed-door meetings on clinical AI

Summary

Federal health officials are holding closed-door meetings with technology companies, researchers, and lobbyists as they consider how to accelerate clinical AI adoption.

The meetings signal that regulators are moving from broad interest in clinical AI toward policies

Why it matters

The resulting framework could determine how quickly AI enters patient care and who bears responsibility when it fails.

Link to Story

Other Developments

A curated list of other prominent stories from this day.

11:32 PMScienceDaily

Dirty air may trigger painful rheumatoid arthritis flares

Summary

Tiny particles from smoke, soot, and dust may worsen rheumatoid arthritis and increase the risk of painful flares, especially after prolonged exposure. The findings suggest that air quality could influence disease activity.

Prolonged exposure to particulate pollution may add an environmental trigger to rheumatoid arthritis, a disease

Why it matters

Air pollution could become a preventable factor in managing rheumatoid arthritis symptoms.

Link to Story

11:16 PMScienceDaily

THC medication made PTSD nightmares disappear for more than a third of patients

Summary

A prescription THC treatment eliminated recurring trauma-related nightmares for more than one-third of people with PTSD after ten weeks. The result points to a potential treatment for a symptom that often persists despite existing care.

The key shift is that a prescription THC formulation produced complete nightmare relief for a

Why it matters

A targeted treatment for persistent PTSD nightmares could address a major gap in symptom control.

Link to Story

5:24 PMWWD

The 12 Best Blackhead Removal Tools for Clearing Your Skin This Summer, According to Dermatologists

Summary

Dermatologists recommend a range of products for removing blackheads, from pore strips costing $8 to higher-tech devices. The selection focuses on tools intended to clear clogged pores during the summer.

The market spans inexpensive disposable products and more costly gadgets, giving consumers several ways to

Why it matters

Blackhead care illustrates how expert-backed consumer skincare continues to expand across price points.

Link to Story

5:07 PMBloomberg Markets

Big Take: The $19 Billion Menopause Economy

Summary

The menopause treatment market has grown into a $19 billion industry, drawing companies into a rapidly expanding commercial opportunity. The boom has not reached all women equally.

The market is expanding faster than access, leaving some women excluded from new treatments and

Why it matters

Menopause is becoming a major healthcare market, but growth alone will not resolve gaps in access.

Link to Story

4:41 PMStat News

STAT+: Takeda’s narcolepsy drug approved by the FDA, seen as a boon for new class of treatments

Summary

The FDA approved Takeda’s narcolepsy treatment, marking a regulatory win for a novel drug class. Researchers hope the same approach could eventually address other conditions.

The approval gives the emerging drug class its first major clinical validation and expands options

Why it matters

A successful new treatment platform could reshape narcolepsy care and open a path to therapies for other neurological disorders.

Link to Story

10:04 AMMarketWatch

Changing how Medicare pays for hospice care could save the U.S. $7.6 billion a year — but at what cost to patients?

Summary

A proposed change to Medicare’s hospice payment system could save the federal government $7.6 billion annually. Hospice providers argue that the current model gives them flexibility to tailor care to individual patients.

The central tradeoff is lower federal spending versus less flexibility in end-of-life care. A payment

Why it matters

Medicare policy could reduce costs while changing how much support dying patients and their families receive.

Link to Story

2:22 PMBloomberg Markets

AstraZeneca Is Said to Have Explored Bristol Myers Merger

Summary

AstraZeneca has explored acquiring Bristol Myers Squibb, according to people familiar with the matter. The potential transaction would be the largest merger in the pharmaceutical industry.

The talks, if pursued, would signal that scale and pipeline depth are driving another wave

Why it matters

A deal of this size could reset pharmaceutical industry valuations and concentrate power over major drug pipelines.

Link to Story

2:10 PMStat News

STAT+: Could poop pills be the next treatment for food allergies?

Summary

A small trial found that some participants became more tolerant of peanuts after receiving a fecal microbiome transplant in pill form. The findings suggest that gut bacteria may influence food allergy responses, but they remain preliminary.

The early signal points to the microbiome as a possible target for treating food allergies

Why it matters

If validated, microbiome-based treatment could offer a new way to reduce the danger of severe food-allergic reactions.

Link to Story

12:18 PMCNBC

Bank of America spends $250 million a year on GLP-1 drugs for its employees, CEO says

Summary

Bank of America spends about $250 million annually on GLP-1 drugs for employees, reflecting the high cost of covering medicines such as Ozempic and Wegovy. Employers are facing sustained demand for these treatments despite their multithousand-dollar annual price tags.

The spending shows that GLP-1 coverage has become a major employer health-benefit expense rather than

Why it matters

GLP-1 drugs are reshaping employer healthcare budgets and benefit design.

Link to Story

10:15 AMCNBC

CVS blows past estimates, hikes guidance as insurance unit continues to improve

Summary

CVS exceeded quarterly expectations and raised its outlook as its insurance business continued to recover. It also partnered with Eli Lilly to offer eligible patients access to Zepbound and Foundayo through the CVS Health app.

The insurance unit’s improvement is restoring confidence in CVS’s core earnings and giving management room

Why it matters

CVS is combining an improving insurance business with direct distribution of obesity drugs, strengthening its influence over how patients obtain them.

Link to Story

9:58 AMAl Jazeera

Boxer Chapman recovering after emergency surgery for brain bleed

Summary

Featherweight boxer Raven Chapman is recovering after collapsing during sparring on July 24 and undergoing emergency surgery for a brain bleed, according to her team.

The incident underscores the potentially catastrophic consequences of head trauma in combat sports, even during

Why it matters

A serious training-room brain injury puts athlete safety protocols in combat sports under renewed focus.

Link to Story

9:32 AMStat News

STAT+: Moderna launches early trial of Ebola mRNA vaccine

Summary

Moderna has launched an early-stage clinical trial of an mRNA vaccine targeting Ebola. The trial marks an initial test of whether the platform can be applied to a disease with substantial outbreak risk but limited commercial demand.

An Ebola program tests mRNA technology beyond the large markets that drove its initial growth.

Why it matters

The trial could show whether mRNA vaccines can address diseases that offer little conventional commercial incentive.

Link to Story

9:29 AMStat News

STAT+: Why Schrödinger CEO Ramy Farid changed how he’s thinking about AI

Summary

Schrödinger CEO Ramy Farid is rethinking the company's approach to artificial intelligence. The discussion also covers Recursion's neuron map and other developments in health AI.

The shift suggests that AI strategy in drug discovery is moving from broad enthusiasm toward

Why it matters

Drug developers are becoming more selective about which AI applications can produce real scientific and commercial gains.

Link to Story

6:00 AMGothamist

Child poisoned as NYC special education classrooms lag in lead-paint inspections

Summary

An analysis found that New York City classrooms serving students with disabilities are less likely to receive lead-paint inspections, even though children in those settings may face greater exposure risks. A child was poisoned at The Bronx School for Continuous Learners.

The decisive failure is uneven inspection coverage in classrooms where vulnerable children spend their days.

Why it matters

Weak inspection standards can turn an existing disability risk into a preventable public-health threat.

Link to Story

12:00 AMFinancial Times

The ethical perils of gene therapy

Summary

A case in China illustrates the risks surrounding gene therapy, a treatment with the potential to produce profound medical benefits but also serious ethical consequences.

The central shift is that gene therapy's risks extend beyond technical safety to questions of

Why it matters

Gene therapy can permanently alter patients' lives, making weak oversight especially difficult to reverse.

Link to Story

Make it yours

Build Your First Pass.

Pick your topics, set your cadence, and receive your personalized First Pass in your inbox. It’s that simple!